Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...

Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

Acquisition of the constitutively active Janus kinase 2 (JAK2)V617F mutation occurs in almost all patients with polycythaemia vera (PV) and in a significant number of patients with essential ...

Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Fedratinib is a selective oral Janus kinase 2 (JAK2) inhibitor. It works by targeting enzyme pathways that promote cancer cell growth and proliferation. “Several clinical trials presented at the ...

Another 45 years passed before the discovery of a first genetic driver of non-Ph MPNs, a mutation in the Janus kinase 2 (JAK2 ...

CALR mutations occur in about 20% of patients with primary and post-essential thrombocythemia myelofibrosis, as per the study ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025" report ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's ...